Assess whether related-party sales should be backed out of valuation (61476f)

SITUATION In a strategic buyer looking at a carve-out from a conglomerate, regulatory-approval critical-path calendar is the evidence after a Phase II that found groundwater impact. IP diligence counsel's financial counterpart has to pick Proceed or Reprice for this M&A Due Diligence Earnings and Revenue Quality close using regulatory-approval critical-path calendar.

DECISION IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a Phase II that found groundwater impact.

HYPOTHESES TO TEST 1. Authorize Proceed now; regulatory-approval critical-path calendar already has the discriminator after a Phase II that found groundwater impact. 2. Keep Reprice in force until regulatory-approval critical-path calendar is completed after a Phase II that found groundwater impact for IP diligence counsel's financial counterpart. 3. Treat regulatory-approval critical-path calendar as Walk because both readings appear after a Phase II that found groundwater impact. 4. Refuse a M&A Due Diligence close: IP diligence counsel's financial counterpart does not have the decision related-party sales should be turns on in regulatory-approval critical-path calendar.

ANALYSIS REQUIRED 1. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to related-party sales should be. 2. Name the document IP diligence counsel's financial counterpart still needs before signing. 3. Test whether a Phase II that found groundwater impact is a diligence gap, a price chip, or a walk-away. 4. For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against a Phase II that found groundwater impact and write the one fact that would move related-party sales should be for IP diligence counsel's financial counterpart.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after a Phase II that found groundwater impact). The follow-on Earnings and Revenue Quality action is what IP diligence counsel's financial counterpart does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for IP diligence counsel's financial counterpart - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Named option among Proceed, Reprice, Walk and the fact that kills the others - Owner and next date for IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate